U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A		^{US-} 4,889,129	12/26/89	Dougherty et al.	
1		^{US-} 5,196,709	03/23/93	Berndt et al.	
1		^{US-} 5,660,181	08/26/97	Ho et al.	
3/		^{US-} 6,180,087	01/30/01	Achilefu et al.	
		US-			
***		US-			
		US-			
		US-			
	-	US-			_
		US-	<u> </u>		
		US-			
		US-			
	 	US-			
	 	US-	 		
	 	US-	· · · · -		
		US-	+	<u> </u>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (# known)	MM-DD-YYYY	,,	Or Relevant Figures Appear	T ⁶		
	ļ					┡		
· · · · · · · · · · · · · · · · · · ·	-					╄		
						┢		
						Т		

Examiner Signature Considered 8/16/6 6

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. (Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO			Complete if Known			
Jubanut	18 101 10HH 1448/F10			Application Numb r			
INFO	ORMATION	DIS	CLOSURE	Filing Date	09/22/03		
STATEMENT BY APPLICANT				First Named Inventor	Winston Zonh Ho		
				Art Unit			
	(Use as many she	ets as n	ecessa <i>ry)</i>	Examiner Name			
Sheet	2	of	2	Attorney Docket Number			

		NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ST		OMOEFE O. ABUGO, et al; "Fluorescence Properties of Rhodamine 800 in whole Blood and Plasma"; Analytical Biochemistry 279; pp142-150 (2000)	
1		OMOEFE O. ABUGO, et al; "Fluorescent Measurements in Whole Blood and Plasma Using Red Emitting Dyes"; Proceedings of SPIE Vol. 3913; pp145-159 (2000)	
		AETNA INC.; "Indocyanine Green Angiography"; Aetna Clinical Policy Bulletins, Number 111; www.aetna.com	
		DONALD S. FONG, et al; "Indocyanine Green Angiography"; Ophthalmology Vol. 105; pp1564-1569 (August 1998)	
		PAUL M. BEER, et al; "Indocyanine Green Angiographic Findings in Toxemia of Pregnancy"; The Vitreous Society Online Journal; www.vitreoussociety.org (June 1, 1998)	
		KRYSTYNA URBANSKA, et al; "Indocyanine Green as a Prospective Sensitizer for Photodynamic Therapy of Melanomas"; Acta Biochimica Polonica Vol. 49 No. 2; pp387-391 (2002)	
		A. TULPULE, et al; "Indocyanine Green Clearance in the Undernourished Adults"; Indian Journal of Pharmacology Vol. 17; pp197-200 (1985)	

	<u></u>		
Examiner	1	Date	alu la
Signature ON		Considered	8/14/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.